Medical News / Newly reported from ESC 2023 - Diabetes Dialogue: STEP-HFpEF Reaction

For endocrinologists and the diabetes care team, GLP-1 receptor agonists have been a familiar face for nearly 2 decades. In recent years, as its role has expanded into chronic weight management, healthcare professionals outside of these disciplines have begun to familiarize themselves with the class. In August 2023, it became evident cardiology would be the next specialty to find a role for at least one member of the class, with data from the SELECT and STEP-HFpEF trials purporting significant cardiovascular benefit from use of semaglutide 2.4 mg (Wegovy) in patient populations with obesity. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more
At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more
Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more
For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more